1. Home
  2. LENZ vs IPHA Comparison

LENZ vs IPHA Comparison

Compare LENZ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LENZ Therapeutics Inc.

LENZ

LENZ Therapeutics Inc.

HOLD

Current Price

$5.57

Market Cap

198.8M

Sector

Health Care

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.90

Market Cap

189.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LENZ
IPHA
Founded
2019
1999
Country
United States
France
Employees
N/A
163
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.8M
189.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
LENZ
IPHA
Price
$5.57
$1.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$44.00
$5.75
AVG Volume (30 Days)
610.6K
14.1K
Earning Date
05-06-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,088,000.00
N/A
Revenue This Year
$50.42
$180.36
Revenue Next Year
$197.16
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.73
$1.18
52 Week High
$50.19
$2.63

Technical Indicators

Market Signals
Indicator
LENZ
IPHA
Relative Strength Index (RSI) 26.32 58.62
Support Level N/A $1.73
Resistance Level $10.42 $1.90
Average True Range (ATR) 0.43 0.08
MACD -0.05 0.00
Stochastic Oscillator 0.56 76.43

Price Performance

Historical Comparison
LENZ
IPHA

About LENZ LENZ Therapeutics Inc.

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: